Vetoquinol (VETO.PA) Stock Price

Vetoquinol Price

Euronext·CLOSED
71.30EUR+0.20 (+0.28 %)
Market closed

Revenue has compounded at 4.9% per year over the past 19 years to 525.70 M EUR. Earnings per share have grown at 6.6% per year over the last 19 years. Vetoquinol's net margin stands at 10.9%, down from 12.1% several years earlier. Vetoquinol currently offers a dividend yield of about 1.25%. The payout ratio is around 19% of earnings. The dividend has grown at 7.8% per year over the past 18 years. Analysts set a median price target of 90.78 EUR, implying 27.3% above the current price. Of 11 analysts, 8 rate the stock a buy — an overall Buy consensus. The stock trades about 5% above its 52-week low.

Vetoquinol stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Vetoquinol over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Vetoquinol stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Vetoquinol's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Vetoquinol Stock Price History
DateVetoquinol Price
8/6/202671.30 EUR
8/5/202671.10 EUR
8/4/202673.10 EUR
7/31/202673.00 EUR
7/30/202673.00 EUR
7/29/202673.00 EUR
7/28/202672.30 EUR
7/27/202672.60 EUR
7/24/202671.50 EUR
7/23/202671.10 EUR
7/22/202671.70 EUR
7/21/202671.80 EUR
7/20/202671.10 EUR
7/17/202672.60 EUR
7/16/202672.70 EUR
7/15/202672.60 EUR
7/14/202671.90 EUR
7/13/202671.80 EUR
7/10/202671.00 EUR
7/9/202671.30 EUR
7/8/202671.60 EUR
7/7/202672.50 EUR
7/6/202671.60 EUR
7/3/202670.80 EUR
7/2/202671.80 EUR
7/1/202671.00 EUR
6/30/202670.90 EUR
6/29/202672.00 EUR
6/26/202672.40 EUR
6/25/202671.90 EUR
6/24/202672.10 EUR
6/23/202672.40 EUR
6/22/202670.80 EUR
6/19/202669.60 EUR
6/18/202669.50 EUR
6/17/202668.90 EUR
6/16/202670.40 EUR
6/15/202670.90 EUR
6/12/202670.20 EUR
6/11/202670.80 EUR
6/10/202670.50 EUR
6/9/202670.10 EUR
6/8/202670.00 EUR
6/5/202670.00 EUR
6/4/202667.90 EUR
6/3/202668.40 EUR
6/2/202669.90 EUR
6/1/202671.20 EUR
5/29/202672.70 EUR
5/28/202672.60 EUR
5/27/202672.60 EUR
5/26/202673.20 EUR
5/25/202672.20 EUR
5/22/202672.00 EUR
5/21/202672.20 EUR
5/20/202671.20 EUR
5/19/202672.30 EUR
5/18/202671.60 EUR
5/15/202671.00 EUR
5/14/202672.30 EUR
5/13/202671.00 EUR
5/12/202672.10 EUR
5/11/202673.00 EUR
5/8/202674.30 EUR
5/7/202675.70 EUR
5/6/202676.10 EUR
5/5/202674.20 EUR
5/4/202674.40 EUR
4/30/202677.00 EUR
4/29/202677.10 EUR
4/28/202680.50 EUR
4/27/202680.00 EUR
4/24/202681.90 EUR
4/23/202680.60 EUR
4/22/202680.90 EUR
4/21/202682.50 EUR
4/20/202684.00 EUR
4/17/202680.00 EUR
4/16/202679.60 EUR
4/15/202680.00 EUR
4/14/202680.00 EUR
4/13/202679.50 EUR
4/10/202680.20 EUR
4/9/202677.70 EUR
4/8/202678.60 EUR
4/7/202679.15 EUR
4/2/202678.20 EUR
3/27/202677.70 EUR
3/26/202679.71 EUR
3/25/202679.70 EUR
3/24/202679.24 EUR
3/23/202678.22 EUR
3/20/202679.02 EUR
3/19/202679.25 EUR
3/17/202676.78 EUR
3/16/202676.70 EUR
3/13/202678.05 EUR
3/12/202679.16 EUR
3/11/202681.30 EUR
3/10/202680.00 EUR
3/9/202677.00 EUR
3/6/202679.30 EUR
3/5/202681.90 EUR
2/27/202684.85 EUR
2/26/202684.98 EUR
2/25/202685.30 EUR
2/24/202684.22 EUR
2/23/202686.66 EUR
2/20/202686.74 EUR
2/19/202686.24 EUR
2/18/202688.02 EUR
2/17/202688.18 EUR
2/16/202691.01 EUR
2/13/202691.00 EUR
2/12/202689.75 EUR
2/11/202686.00 EUR
2/10/202686.82 EUR
2/9/202686.72 EUR
2/6/202686.36 EUR
2/5/202685.24 EUR
2/4/202686.89 EUR
2/3/202686.03 EUR
2/2/202684.77 EUR
1/30/202686.77 EUR
1/29/202685.06 EUR
1/28/202685.20 EUR
1/27/202685.82 EUR
1/26/202685.19 EUR
1/23/202683.94 EUR
1/22/202684.07 EUR
1/21/202683.19 EUR
1/20/202684.06 EUR
1/19/202684.18 EUR
1/17/202685.10 EUR
1/15/202685.80 EUR
1/14/202685.20 EUR
1/13/202685.53 EUR
1/12/202686.00 EUR
1/9/202686.26 EUR
1/8/202685.63 EUR
1/7/202685.67 EUR
1/6/202685.39 EUR
1/5/202685.98 EUR
1/2/202683.40 EUR
12/31/202583.60 EUR
12/30/202583.64 EUR
12/29/202583.85 EUR
12/24/202584.00 EUR
12/23/202583.44 EUR
12/22/202580.80 EUR
12/19/202580.18 EUR
12/18/202578.93 EUR
12/17/202578.17 EUR
12/16/202577.50 EUR
12/15/202577.24 EUR
12/12/202576.75 EUR
12/11/202577.20 EUR
12/10/202577.01 EUR
12/9/202577.14 EUR
12/8/202577.51 EUR
12/5/202573.86 EUR
12/4/202572.40 EUR
12/3/202572.04 EUR
12/2/202571.48 EUR
12/1/202572.57 EUR
11/28/202572.50 EUR
11/27/202572.72 EUR
11/26/202571.90 EUR
11/25/202571.72 EUR
11/24/202571.59 EUR
11/21/202570.80 EUR
11/20/202571.75 EUR
11/19/202571.80 EUR
11/18/202570.81 EUR
11/17/202571.02 EUR
11/14/202572.15 EUR
11/13/202573.35 EUR
11/12/202573.59 EUR
11/11/202572.48 EUR
11/10/202572.04 EUR
11/7/202571.97 EUR
11/6/202572.37 EUR
11/5/202572.70 EUR
11/4/202573.82 EUR
11/3/202574.60 EUR
10/31/202574.35 EUR
10/30/202574.00 EUR
10/29/202574.99 EUR
10/28/202578.40 EUR
10/27/202578.71 EUR
10/24/202577.00 EUR
10/23/202578.30 EUR
10/22/202577.50 EUR
10/21/202577.43 EUR
10/20/202577.42 EUR
10/17/202578.50 EUR
10/16/202578.49 EUR
10/15/202577.64 EUR
10/14/202576.31 EUR
10/13/202577.45 EUR
10/10/202578.31 EUR
10/9/202579.38 EUR
10/8/202579.44 EUR
10/7/202579.15 EUR
10/6/202578.60 EUR
10/3/202578.62 EUR
10/2/202578.63 EUR
10/1/202579.10 EUR
9/30/202577.10 EUR
9/29/202576.50 EUR
9/26/202577.30 EUR
9/25/202576.20 EUR
9/24/202575.20 EUR
9/23/202578.90 EUR
9/22/202577.31 EUR
9/19/202578.41 EUR
9/18/202578.80 EUR
9/17/202579.89 EUR
9/16/202580.23 EUR
9/15/202582.05 EUR
9/12/202581.68 EUR
9/11/202572.53 EUR
9/10/202572.78 EUR
9/9/202572.36 EUR
9/8/202572.82 EUR
9/5/202575.41 EUR
9/4/202573.61 EUR
9/3/202572.46 EUR
9/2/202573.71 EUR
9/1/202575.50 EUR
8/29/202575.20 EUR
8/28/202575.22 EUR
8/27/202577.20 EUR
8/26/202572.80 EUR
8/25/202574.35 EUR
8/22/202575.00 EUR
8/21/202575.15 EUR
8/20/202575.55 EUR
8/19/202576.34 EUR
8/18/202574.64 EUR
8/15/202574.80 EUR
8/14/202575.24 EUR
8/13/202574.00 EUR
8/12/202574.30 EUR
8/11/202574.60 EUR
Access this data via the Eulerpool API
Get Free API Key

Vetoquinol Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2021
521.27 M EUR
83.98 M EUR
62.86 M EUR
Jan 1, 2022
539.78 M EUR
74.00 M EUR
48.00 M EUR
Jan 1, 2023
529.27 M EUR
74.26 M EUR
55.56 M EUR
Jan 1, 2024
539.20 M EUR
77.32 M EUR
58.69 M EUR
Jan 1, 2025
525.70 M EUR
73.24 M EUR
57.30 M EUR
Jan 1, 2026 (e)
521.80 M EUR
124.82 M EUR
55.85 M EUR
Jan 1, 2027 (e)
550.96 M EUR
128.96 M EUR
66.56 M EUR
Jan 1, 2028 (e)
559.65 M EUR
133.87 M EUR
63.99 M EUR

Vetoquinol Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 9, 2026, 2:48 AM
 
REVENUEM EUR
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM EUR
EBITM EUR
EBIT MARGIN%
NET INCOMEM EUR
NET INCOME GROWTH%
DIV.EUR
DIV. GROWTH%
SHARESM
20132014201520162017201820192020202120222023202420252026e2027e2028e
299.00315.00342.00350.00352.00367.00395.00427.00521.00539.00529.00539.00525.00521.00550.00559.00
0.345.358.572.340.574.267.638.1022.013.45-1.861.89-2.60-0.765.571.64
49.8350.7950.5851.4352.8453.4151.9028.8132.0531.9155.0171.8030.4830.4830.4830.48
149.00160.00173.00180.00186.00196.00205.00123.00167.00172.00291.00387.00160.00158.78167.62170.36
33.0035.0038.0042.0045.0048.0045.0037.0083.0074.0074.0077.0073.00124.00128.00133.00
11.0411.1111.1112.0012.7813.0811.398.6715.9313.7313.9914.2913.9023.8023.2723.79
23.0025.0024.0027.0034.0036.0028.0019.0062.0047.0055.0058.0057.0055.0066.0063.00
4.558.70-4.0012.5025.935.88-22.22-32.14226.32-24.1917.025.45-1.72-3.5120.00-4.55
0.350.370.390.410.430.460.480.380.500.800.800.850.891.011.141.29
6.065.715.415.134.886.984.35-20.8331.5860.00–6.254.7113.4812.8713.16
11.9411.9211.8611.8511.8611.8311.8311.8311.8311.8311.8311.8011.9711.9711.9711.97
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Vetoquinol generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Vetoquinol retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Vetoquinol's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Vetoquinol has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Vetoquinol's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Vetoquinol stock margins

The Vetoquinol margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Vetoquinol. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Vetoquinol.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
32.11 %
16.11 %
12.06 %
Jan 1, 2022
31.93 %
13.71 %
8.89 %
Jan 1, 2023
55.05 %
14.03 %
10.50 %
Jan 1, 2024
71.86 %
14.34 %
10.88 %
Jan 1, 2025
30.50 %
13.93 %
10.90 %
Jan 1, 2026 (e)
30.50 %
23.92 %
10.70 %
Jan 1, 2027 (e)
30.50 %
23.41 %
12.08 %
Jan 1, 2028 (e)
30.50 %
23.92 %
11.43 %

Vetoquinol Stock Revenue, EBIT, Earnings per Share

The Vetoquinol earnings per share therefore indicates how much revenue Vetoquinol has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
44.06 EUR
7.10 EUR
5.31 EUR
Jan 1, 2022
45.62 EUR
6.25 EUR
4.06 EUR
Jan 1, 2023
44.72 EUR
6.28 EUR
4.69 EUR
Jan 1, 2024
45.70 EUR
6.55 EUR
4.97 EUR
Jan 1, 2025
43.90 EUR
6.12 EUR
4.79 EUR
Jan 1, 2026 (e)
44.24 EUR
10.42 EUR
4.74 EUR
Jan 1, 2027 (e)
46.71 EUR
10.77 EUR
5.64 EUR
Jan 1, 2028 (e)
47.45 EUR
11.18 EUR
5.43 EUR

Vetoquinol business model & stock analysis

Vetoquinol SA is a French company specializing in animal health products and is one of the leading organizations in this field worldwide. It was founded in 1933 and is headquartered in Lure, France.

Vetoquinol SWOT Analysis

Strengths

  • Vetoquinol SA is a leading global player in the animal health market, with a strong presence in both developed and emerging markets.
  • The company has a diverse portfolio of high-quality products for both companion and production animals.
  • Vetoquinol SA has a long-standing history in the industry, with over 80 years of experience, which has earned it a strong reputation.
  • The company has a well-established marketing and distribution network, ensuring a wide reach and accessibility of its products.

Weaknesses

  • Vetoquinol SA's dependency on a few key products for a significant portion of its revenue poses a risk in case of product failures or fluctuations in demand.
  • The company's focus on international markets exposes it to regulatory and political risks in different countries.
  • Vetoquinol SA may face challenges in keeping up with rapidly changing technologies and innovations in the animal health industry.

Opportunities

  • The growing global demand for animal protein and increased pet ownership presents opportunities for Vetoquinol SA to expand its customer base and product offerings.
  • Emerging markets, such as Asia and Latin America, offer untapped potential for Vetoquinol SA to enter and establish a stronger presence.
  • Strategic partnerships and collaborations with research institutions or other industry players can enhance Vetoquinol SA's research and development capabilities.

Threats

  • Intense competition from other global animal health companies may put pressure on Vetoquinol SA's market share and pricing strategies.
  • Economic downturns or recessionary periods can impact consumer spending on animal health products, affecting Vetoquinol SA's revenue.
  • Regulatory changes related to animal welfare, antibiotic use, or environmental concerns may require Vetoquinol SA to adapt its products and practices.

Vetoquinol Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Vetoquinol historical P/E ratio, EBIT multiple, and P/S ratio

Vetoquinol annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Vetoquinol shares outstanding

The number of shares of Vetoquinol was 11.97 M in 2025. This indicates how many shares Vetoquinol is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
11.83 M Stocks
Jan 1, 2022
11.83 M Stocks
Jan 1, 2023
11.83 M Stocks
Jan 1, 2024
11.80 M Stocks
Jan 1, 2025
11.97 M Stocks
Jan 1, 2026 (e)
11.97 M Stocks
Jan 1, 2027 (e)
11.97 M Stocks
Jan 1, 2028 (e)
11.97 M Stocks

Vetoquinol Dividend History

19 years of dividend payments · 2 consecutive increases

YearAnnual DividendYoY ChangePayments
20250.89EUR↑ 4.7%1×
Jun 4, 20250.89EUR↑ 4.7%1/1
20240.85EUR↑ 6.2%1×
20230.80EUR 0.0%1×
20220.80EUR↑ 60.0%1×
20210.50EUR↑ 31.6%1×
20200.38EUR↓ 20.8%1×
20190.48EUR↑ 4.3%1×
20180.46EUR↑ 7.0%1×
20170.43EUR↑ 4.9%1×
20160.41EUR↑ 5.1%1×

Vetoquinol dividend history and estimates

In 2025, Vetoquinol paid a dividend amounting to 0.89 EUR. Dividend means that Vetoquinol distributes a portion of its profits to its owners.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details
Date
Dividend
Dividend (Estimate)
Jan 1, 2021 (e)
0.00 EUR
0.50 EUR
Jan 1, 2022
0.80 EUR
0.00 EUR
Jan 1, 2023
0.80 EUR
0.00 EUR
Jan 1, 2024
0.85 EUR
0.00 EUR
Jan 1, 2025
0.89 EUR
0.00 EUR
Jan 1, 2026 (e)
0.00 EUR
1.01 EUR
Jan 1, 2027 (e)
0.00 EUR
1.14 EUR
Jan 1, 2028 (e)
0.00 EUR
1.29 EUR

Vetoquinol dividend payout ratio

In 2025, Vetoquinol had a payout ratio of 18.60%. The payout ratio indicates the percentage of the company's profits that Vetoquinol distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2021
9.41 %
Jan 1, 2022
19.72 %
Jan 1, 2023
17.04 %
Jan 1, 2024
17.09 %
Jan 1, 2025
18.60 %
Jan 1, 2026 (e)
21.27 %
Jan 1, 2027 (e)
20.19 %
Jan 1, 2028 (e)
23.76 %

Current Vetoquinol forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
1.14 %
Buy
72.73 % (8)
Hold
27.27 % (3)
Sell
0.00 % (0)
12M Price Target
90.78
Last Price
71.30
Currency
EUR
12M Return Potential
27.32 %
LTM Return
0 %

Vetoquinol shareholder structure

% Name
3.30274%
Fidelity Management & Research Company LLC
Fidelity Management & Research Company LLC
1.55293%
Oddo BHF Asset Management S.A.S
Oddo BHF Asset Management S.A.S
0.96405%
BNP Paribas Asset Management UK Limited
BNP Paribas Asset Management UK Limited
0.87898%
AXA Investment Managers UK Ltd.
AXA Investment Managers UK Ltd.
0.72954%
Invesco Advisers, Inc.
Invesco Advisers, Inc.
0.72165%
Danske Bank Asset Management
Danske Bank Asset Management

Vetoquinol Beneficial Ownership Filings (SEC 13D/G)

Free Float
31.4%
Float Shares
-
Shares Outstanding
-

Vetoquinol Executives and Management Board

10 members · avg. age 64 · 40 % women

MF

Mr. Matthieu Frechin (56)

Chairman of the Board, Chief Executive Officer · since 2001

393,733.00 EUR

Management

DD

Mr. Dominique Derveaux (56)

Group Chief Operating Officer · since 2020

365,836.00 EUR
AM

Mr. Alain Masson (63)

Deputy Chief Executive Officer and Head Pharmacist, Group Quality Director

197,812.00 EUR

Board of Directors

MF

Mr. M. Luc Frechin (52)

Director

23,100.00 EUR
PA

Mr. Philippe Arnold (84)

Independent Director

23,100.00 EUR
MB

Ms. Marie-Josephe Baud (76)

Independent Director

23,100.00 EUR
LC

Mr. Louis Champel (81)

Independent Director

23,100.00 EUR
AG

Mrs. Anne Graffin (64)

Independent Director

23,100.00 EUR
AC

Mrs. Audrey Chanoinat (46)

Director

21,000.00 EUR

Vetoquinol Supply Chain

Vetoquinol Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
2 companies
#Nameβ 1YTrend
1
Covetrus Inc
Customer·Health Care Providers & Services·US
0.90
0.49
0.22
0.10
-0.52
-0.52
—
2
Orion B
Supplier·Customer·Pharmaceuticals·FI
0.83
0.63
0.80
0.44
0.17
-0.33
0.16

Frequently asked questions about Vetoquinol

Vetoquinol SA, a renowned company in the veterinary pharmaceutical industry, follows a comprehensive business model. The company primarily focuses on the development, manufacturing, and distribution of veterinary medicines and products. Through its wide range of high-quality medications, vaccines, and supplements, Vetoquinol aims to improve animal health and well-being. By collaborating with veterinarians and pet owners worldwide, the company provides solutions for both production animals and pets. With a strong commitment to research and development, Vetoquinol constantly innovates its product portfolio to address evolving veterinary needs. This business model enables Vetoquinol SA to contribute significantly towards animal healthcare, upholding its position as a leader in the industry.

Vetoquinol SA is primarily active in the animal health industry.

The main competitors of Vetoquinol SA in the market include industry players such as Zoetis Inc., Elanco Animal Health Inc., and Merck Animal Health. These companies also operate in the animal health sector and offer a range of pharmaceutical and veterinary products, similar to Vetoquinol SA. Vetoquinol SA faces competition from these companies in terms of product offerings, market share, and innovation. However, Vetoquinol SA has established a strong presence in the market with its high-quality veterinary medicines and solutions, maintaining a competitive edge in the industry.

Vetoquinol SA is a leading global animal health company, specializing in providing a wide range of veterinary pharmaceutical products and solutions. Founded in 1933 by Doctor Pierre-Richard Dick, Vetoquinol has a rich history and a strong commitment to animal health. With its headquarters in France, the company has expanded its operations globally, serving customers in over 100 countries. Vetoquinol focuses on developing innovative and high-quality products for both companion animals and livestock. With a dedicated team of experts and a customer-centric approach, Vetoquinol continuously strives to improve animal well-being and contribute to the advancement of veterinary medicine.

Some significant milestones achieved by Vetoquinol SA include: 1. Expansion of Global Presence: Vetoquinol SA has successfully expanded its presence in several global markets, strengthening its position as a leading international animal health company. 2. Strategic Acquisitions: The company has made strategic acquisitions that have broadened its product portfolio and allowed for diversified growth opportunities. These acquisitions have further solidified Vetoquinol SA's position in the animal health industry. 3. Innovative Product Development: Vetoquinol SA has continuously focused on research and development, leading to the introduction of innovative animal health products. This commitment to innovation has helped the company provide effective solutions for veterinarians and pet owners alike. 4. Sustainable Initiatives: Vetoquinol SA has shown a strong commitment to sustainability, implementing various initiatives to reduce its environmental footprint and support responsible practices within the industry. It is important to note that while the company name may appear frequently in the answer to ensure SEO optimization, the content should prioritize providing accurate and relevant information about Vetoquinol SA's milestones.

Vetoquinol SA is primarily present in various countries and regions worldwide. It has a prominent presence in Europe, particularly in France where its headquarters are based. Apart from its significant market presence in France, the company extends its operations across other European countries, such as Germany, Italy, Spain, and the United Kingdom. In addition, Vetoquinol SA has established a strong presence in the Americas, including the United States, Mexico, and Brazil. The company is also active in Asia, with operations in China, India, and Japan, among others. Furthermore, Vetoquinol SA serves the veterinary market in Africa and Oceania.

Vetoquinol SA represents values of innovation, expertise, and commitment to animal health. With a strong corporate philosophy focused on the well-being and care of animals, Vetoquinol SA strives to develop and provide effective veterinary medicines and services. This leading animal health company aims to improve the quality of life for pets, livestock, and other animals worldwide. With its extensive research and development efforts, Vetoquinol SA consistently introduces innovative solutions, ensuring the highest standards of animal health. With a passion for animals, Vetoquinol SA remains dedicated to nurturing the bond between humans and their beloved pets through science-based veterinary care.

Analysts currently set an average price target of 95.12 EUR for the Vetoquinol stock (median: 90.78 EUR), implying +33.4 % versus the latest price. The consensus is based on 11 analyst ratings.

Vetoquinol Analyst Price Targets 2026

11 analysts currently rate the Vetoquinol stock: 8 recommend buying, 3 holding and 0 selling. For 2026, analysts expect Vetoquinol to generate revenue of 521.80 M EUR and earnings per share of 4.66 EUR.

Vetoquinol Analyst Price Targets 2026

The Vetoquinol share (VETO.PA) is listed on 6 stock exchanges, including: Frankfurt (8JM.F), München (8JM.MU), London (0O1O.L), London (0O1O.L), Paris (VETO.PA).

Vetoquinol SA is a leading global company in the animal health industry, offering a wide range of products and services for pets, livestock, and other animals. The company is headquartered in France and operates in over 100 countries worldwide. Vetoquinol SA's divisions include four main areas: 1. Pharmaceuticals: Vetoquinol SA has a wide range of pharmaceuticals for pets, livestock, and other animals. The pharmaceutical products are divided into categories such as antibiotics, antifungals, anti-inflammatory agents, parasiticides, anthelmintics, nutrients, and other medications. 2. Nutritional supplements: Vetoquinol SA offers a wide range of nutritional supplements for pets, livestock, and other animals. These products have been specifically developed to provide optimal nutrition to animals and improve their health and well-being. 3. Vaccines: Vetoquinol SA produces vaccines for pets, livestock, and other animals. The vaccines protect animals from infectious diseases and improve overall health. 4. Services: Vetoquinol SA provides a wide range of services for veterinarians and animal owners. These include training, technical support, consulting, and other value-added services. Vetoquinol SA's business model focuses on improving the health and well-being of animals through innovative products and services. The company aims to offer high-quality products and services at a fair price and adopts a holistic approach to animal health. Some of the key products from Vetoquinol SA are the antibiotics Vetrimoxin® (Amoxicillin) and Enrofloxacin, as well as the antifungals Amphotericin B, Ketoconazole, and Fluconazole. The company also produces a wide range of nutritional supplements such as Joint Force™, Calopet™, and Bio-Cat™. Furthermore, Vetoquinol SA manufactures vaccines such as Leucogen®, Leucoguard®, and Equilis®. Vetoquinol SA strives to understand the needs of its customers and offer innovative products and services tailored to the needs of animals and their owners. The company has a wide network of distribution partners worldwide to ensure that its products and services are available to veterinarians and animal owners. Overall, Vetoquinol SA's business model is focused on improving the health and well-being of animals. The company aims to provide high-quality products and services and support its customers through training, consulting, and technical support.

The expected revenue of Vetoquinol is 521.80 M EUR. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Vetoquinol is 55.85 M EUR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Vetoquinol is currently 15.29. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Vetoquinol stock.

The price-to-sales ratio (P/S) of Vetoquinol is currently 1.64. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Vetoquinol stock.

The Eulerpool Quality Score for Vetoquinol is 5/10.

The ISIN of Vetoquinol is FR0004186856. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Vetoquinol is A0LEWB. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Vetoquinol is VETO.PA. The ticker symbol is used to trade Vetoquinol shares on the stock exchange.

Over the past 12 months, Vetoquinol paid a dividend of 0.89 EUR . This corresponds to a dividend yield of about 1.25 %. For the coming 12 months, Vetoquinol is expected to pay a dividend of 1.14 EUR.

The current dividend yield of Vetoquinol is 1.25 %.

Vetoquinol pays a dividend, distributed in the months of , , , .

Vetoquinol paid dividends every year for the past 19 years.

For the upcoming 12 months, dividends amounting to 1.14 EUR are expected. This corresponds to a dividend yield of 1.60 %.

Vetoquinol is assigned to the 'Health' sector.

To receive the latest dividend of Vetoquinol from amounting to 0.89 EUR, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

In the year 2025, Vetoquinol distributed 0.85 EUR as dividends.

The dividends of Vetoquinol are distributed in EUR.

All fundamentals and in-depth analysis of Vetoquinol

Our stock analysis for Vetoquinol stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Vetoquinol. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Vetoquinol Stock
Vetoquinol Revenue→
Vetoquinol Stock
Vetoquinol Net Income→
Vetoquinol Stock
Vetoquinol P/E→
Vetoquinol Stock
Vetoquinol P/S→
Vetoquinol Stock
Vetoquinol EBIT→
Vetoquinol Stock
Vetoquinol Dividend→
Vetoquinol Stock
Vetoquinol Directors Dealings→
Vetoquinol Stock
Vetoquinol Stocks→
Vetoquinol Stock
Vetoquinol Market capitalization→
Vetoquinol Stock
Vetoquinol Debt→
Vetoquinol Stock
Vetoquinol Liabilities→
Vetoquinol Stock
Vetoquinol Equity→
Vetoquinol Stock
Vetoquinol AAQS→
Vetoquinol Stock
Vetoquinol Employees→
Vetoquinol Stock
Vetoquinol ROE→
Vetoquinol Stock
Vetoquinol ROA→
Vetoquinol Stock
Vetoquinol ROCE→
Vetoquinol Stock
Vetoquinol News→
Vetoquinol Stock
Vetoquinol Analyst Price Targets→

Health Stocks

VG Life SciencesVetnostrum Animal Health CoVIA PharmaceuticalsVertex PharmaceuticalsViadermaVerrica PharmaceuticalsViatrisVerisante TechnologyVibhavadi Medical Center PCLVericelVicapsys Life SciencesVerastemAll Stocks A–Z →